HTR1E

Across TCGA pan-cancer cohorts, HTR1E Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated HTR1E data layer compared with 11 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HTR1E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HTR1E expression acts as an unfavorable survival marker, although some lineages such as SKCM and HNSC show a favorable association.

LIHC, ESCA, and SARC are the cancer types where HTR1E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.074	0.781	<.001	36	view →
ESCA	OS	Median	All	0.220	0.708	<.001	24	view →
SARC	OS	Median	All	0.205	0.839	<.001	12	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
SKCM	OS	Median	All	0.962	0.864	.017	10	view →
HNSC	DFS	Median	IV	1.000	0.300	.014	9	view →
LUSC	OS	Median	III,IV	0.265	0.688	.030	9	view →
UCEC	OS	Median	II,III,IV	1.000	0.466	.034	8	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

HTR1E–LIHC (OS)

Open the LIHC breakdown →